C1 esterase inhibitor (human)
Orphan Drug Cold Chain RequiredFDA Approved
Description
C1 esterase inhibitor (human) is a purified plasma-derived concentrate used to treat acute angioedema attacks in patients with hereditary angioedema (HAE). It replaces the missing or dysfunctional C1-INH protein, helping to restore normal regulation of the complement system.
Indications & Therapeutic Use
Hereditary Angioedema
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
C1 esterase inhibitor (human)
| Generic Name | C1 esterase inhibitor (human) |
| Brands | 1 brand available |
| Active Ingredient | C1 esterase inhibitor |
| Drug Class | Hereditary Angioedema |
| Manufacturer | CSL Behring |
| Dosage Forms | Lyophilized powder for reconstitution |
| Medical Code | B06AC01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02581672 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes